Quick Links

Accreditation/Credit Designation

Physicians' Education Resource® LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc. and Novartis Pharmaceuticals Corporation.

Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future Combinations

Release Date: February 28, 2018
Expiration Date: February 28, 2019
Media: Internet - based


Activity Overview

This online activity features an expert panel discussion of the rapidly evolving field of BRAF/MEK inhibitor combination targeted therapy for patients with melanoma. An overview of the cellular pathways that are targeted with BRAF and MEK inhibitors sets the framework for an in-depth discussion pertaining to strategies that inform treatment decisions, including patient characteristics and BRAF testing results. The expert panel will discuss the application of current clinical trial findings to address the use of targeted therapy in the adjuvant and neoadjuvant settings, and management of related toxicities. The panelists will conclude with a discussion of a clinical case and consider the future of melanoma treatment, including the potential role for triplet combinations of targeted therapy plus PD-1/PD-L1‒based immunotherapy.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc. and Novartis Pharmaceuticals Corporation.

CME Table of Contents

  • Introduction
  • Biology Behind Targeted Therapies
  • Medical Crossfire 1-3: Targeted Therapy vs Immunotherapy, Brain Mets, and Toxicities
  • Medical Crossfire 4-6: Role of Adjuvant vs Neoadjuvant Therapy and BRAF Testing
  • Medical Crossfire 7-8: Triplet Combinations of BRAF + MEK + PD-1/PD-L1‒Based Immunotherapy, and BRAF Wild-Type Melanoma
  • Patient Case
  • Medical Crossfire 9: Future of Melanoma Treatment and Conclusions

Requirements for Successful Completion

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, dermatologists, and fellows who treat patients with melanoma. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of melanoma may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Apply clinical trial evidence on evolving targeted treatment strategies for melanoma
  • Develop a multidisciplinary approach for the management of melanoma treatment-related toxicities
  • Discuss the use of biomarkers and key testing technologies that can inform clinical decision making
  • in the management of melanoma
  • Evaluate recent clinical trial evidence to optimally sequence targeted therapies in the management of patients with melanoma

Faculty, Staff, and Planners' Disclosures


Michael A. Postow, MD
Melanoma and Immunotherapeutics Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant/Research Support: BMS, Infinity, Rgenix, Array Biopharma; Consultant: BMS, Merck, Novartis, Incyte, NewLink Genetics, Array Biopharma


Omid Hamid, MD 
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies, The Angeles Clinic and Research Institute
Director of Experimental Therapeutics, Cedars-Sinai Medical Care Foundation
Los Angeles, CA

Disclosure: Consultant: Amgen, Novartis, Roche, BMS, Merck; Speakers Bureau: BMS, Genentech, Novartis, Amgen; Other: Contracted research for institution: AstraZeneca, BMS, Celldex, Genentech, Immunocore, Incyte, Merck, Merck Serono, MedImmune, Novartis, Pfizer, Rinat, Roche

Jason J. Luke, MD, FACP
Assistant Professor of Medicine
The University of Chicago Medicine
Chicago, IL

Disclosure: Consultant: 7 Hills, Actym, Amgen, Array Biopharma, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, Checkmate Pharmaceuticals, EMD Serono, Gilead, Janssen, Merck, NewLink, Nimbus, Novartis, Palleon, RefleXion, Syndax, Tempest, WntRx; Other: Clinical support to institution: AbbVie, Boston Biomedical, Bristol-Myers Squibb, Celldex, Corvus, Delcath, Five Prime, Genentech, Immunocore, Incyte, Intensity, MedImmune, Macrogenics, Novartis, Pharmacyclics, Merck, Tesaro

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Become a Member

Forgot Password?
Calendar of Events
Filter By